Emergent Biosolutions vs Opko Health
Emergent Biosolutions is the larger business, with $743m of revenue in fiscal 2025 against $607m for Opko Health (1.2 times as much). Opko Health grew faster (-14.9% against -28.8%). Emergent Biosolutions kept more of each dollar of sales as profit: a net margin of 7.1% against -37.2%. Opko Health carries less debt relative to equity (27.1% against 112.8%).
| Latest fiscal year | Emergent BiosolutionsEBS, 2025 | Opko HealthOPK, 2025 |
|---|---|---|
| Revenue | $743m | $607m |
| Revenue growth | -28.8% | -14.9% |
| Net income | $52.6m | −$226m |
| Operating margin | 13.5% | -19.3% |
| Net margin | 7.1% | -37.2% |
| Return on equity | 10.5% | -17.1% |
| Free cash flow | $157m | −$191m |
| Cash | $205m | $364m |
| Total debt | $590m | $344m |
| Debt to equity | 112.8% | 27.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $24.9m | $47.0m |
| Employees | 900 | 2,275 |
| Market value | $330m | $1.30bn |
| Price vs our value range | Below our value range | — |
| Moat score | 27 (Weak) | 21 (Weak) |
| Insider trades, 12 months | 0 buys, 15 sales | 33 buys, 0 sales |